Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors

Pancreatic Tumor Clinical Trial

— PACAomics  

Official title:

Research for Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors - PACAomics / IPC 2011-004

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01692873
• Other study ID #: PACAomics / IPC 2011-004
• Status: Completed
• Phase: N/A
• Start date: February 2012
• Est. completion date: December 2017

Study information

• Verified date: August 2018
• Source: Institut Paoli-Calmettes
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat.

Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month.

The aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response.

This project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 274
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Suspicion of pancreatic adenocarcinoma

• Patient > 18 years old

• Social Security affiliation

• Signed informed consent

Exclusion Criteria:

• Patient in emergency situation

• Major person being the object of a legal protective measure or unable to express its consent

Related Conditions & MeSH terms

• Pancreatic Neoplasms
• Pancreatic Tumor

Intervention

Procedure:
• suspected pancreatic tumor
Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.

Locations

Country	Name	City	State
France	Marine GILABERT, MD	Marseille

Sponsors (1)

Lead Sponsor	Collaborator
Institut Paoli-Calmettes

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biomarkers	Genomics, transcriptomics and proteomics analyses to determine presence or absence of biomarkers	within twenty four hours
Secondary	Histology	To determine the histologic characteristics of the pancreatic tumor	within twenty four hours

External Links

•   official web site of the sponsor